Pedro Gonzalez Cabezas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pedro Gonzalez Cabezas has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Beatriz Sánchez-Quiñones
Hybrid Hematology Department, University Hospital Vinalopó, Alicante, Elche, Spain
3 shared publications - Cristina Antón-Maldonado
Hybrid Hematology Department, University Hospital Vinalopó, Alicante, Elche, Spain
3 shared publications - Nataly Ibarra Vega
Hybrid Hematology Department, University Hospital Vinalopó, Alicante, Elche, Spain
3 shared publications - Rafael Carrasco Moreno
University Hospital Vinalopó, Alicante, Spain
3 shared publications - Amparo Santamaria
Hematology Department and Foundation for the Promotion of Health and Biomedical Research (FISABIO), University Vinalopó Hospital, 03293 Elche, Spain
2 shared publications - Maikel Ayo González
Palliative Care Unit, University Hospital Vinalopó, Alicante, Spain
2 shared publications
Latest Publications
- Open Access
- 15 June 2024
- Published by JMIR Publications Inc. in JMIR Preprints
LOLATAO, An Artificial Intelligence-Based virtual Assistant for Clinical Follow-up of Atrial Fibrillation Patients on Oral Anticoagulant Therapy: A Feasibility Pilot Study. (Preprint)
BACKGROUND To reduce the risk of stroke in patients with AF, strict control of the OAT is required. AI-based virtual assistants are proving their usefulness in the monitoring of chronic patients OBJECTIVE In this context, we have launched a pilot study with the aim of evaluating the use of a virtual assistant called LOLATAO, in the follow-up of patients with AF and OAT in our Digital Haemostasis and Thrombosis Unit. METHODS From January to December 2023, we have conducted a prospective observational study of patients with AF and TAO. LOLA, a virtual assistant (software as a medical device – SaMD, Tucuvi) based on AI was used. Patients were selected consecutively according to inclusion criteria. Demographic and clinical-biological data were collected through clinical interviews. All patients received a first contact call and then monthly calls, following a predefined protocol. The study was approved by the CEIM. The responses that should be generated by different types of interventions by the haematologists were established. At the end of the study, a satisfaction questionnaire was carried out on the participating patients RESULTS Fifty patients were included. The mean age was 75 years with 33% women. One-third of the patients (n=16) were with VKAs and two-thirds (33) with DOACs. A total of 579 calls were made with a median follow-up of 278 days. LOLA had high rates of acceptability (85%), adherence (90%) and satisfaction (>95%). The clinical problems detected during follow-up. It was detected that 42% (21) of the patients reported at least one forgetfulness in taking the OAT in the last month, with the most frequent being 1 or 2 doses (34%). 39% (n=19) of the patients reported having had at least one bleeding episode in the last month. All bleeding was mild and none was related to TAO. It should be noted that up to 31% (n=15) of patients reported having presented symptoms of stroke in the last month. However, after conducting a medical interview, it was found that they did not meet the criteria for stroke. 18% (9) of the patients reported having a scheduled intervention and requested an appointment to perform bridging therapy. In patients with VKAs (n=16), 94% (n=15) reported at least once being unaware of their TRT and, after performing an educational intervention, 75% (n=12) of patients reported having a TRT<65%. Those patients in whom TRT was confirmed<65% (9) were switched to DOACs. In patients with DOACs (n=33), in no case did the dose of OAT had to be adjusted. LOLA saved a total of 111h (10 hours per month) for the medical team in the follow-up of patients with AF and OAT. CONCLUSIONS The results of the study suggest that LOLATAO seems to be a tool to help in the management of chronic follow-up of patients with AF and OAT that reduces the burden of care with high rates of acceptance and satisfaction by patients. In addition, it allows the identification of relevant clinical situations that require medical interventions and highlights the lack of knowledge of patients of their pathology and the need to improve their education for greater empowerment. CLINICALTRIAL Not applicable
- 15 June 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessLOLATAO, An Artificial Intelligence-Based virtual Assistant for Clinical Follow-up of Atrial Fibrillation Patients on Oral Anticoagulant Therapy: A Feasibility Pilot Study. (Preprint)
BACKGROUND To reduce the risk of stroke in patients with AF, strict control of the OAT is required. AI-based virtual assistants are proving their usefulness in the monitoring of chronic patients OBJECTIVE In this context, we have launched a pilot study with the aim of evaluating the use of a virtual assistant called LOLATAO, in the follow-up of patients with AF and OAT in our Digital Haemostasis and Thrombosis Unit. METHODS From January to December 2023, we have conducted a prospective observational study of patients with AF and TAO. LOLA, a virtual assistant (software as a medical device – SaMD, Tucuvi) based on AI was used. Patients were selected consecutively according to inclusion criteria. Demographic and clinical-biological data were collected through clinical interviews. All patients received a first contact call and then monthly calls, following a predefined protocol. The study was approved by the CEIM. The responses that should be generated by different types of interventions by the haematologists were established. At the end of the study, a satisfaction questionnaire was carried out on the participating patients RESULTS Fifty patients were included. The mean age was 75 years with 33% women. One-third of the patients (n=16) were with VKAs and two-thirds (33) with DOACs. A total of 579 calls were made with a median follow-up of 278 days. LOLA had high rates of acceptability (85%), adherence (90%) and satisfaction (>95%). The clinical problems detected during follow-up. It was detected that 42% (21) of the patients reported at least one forgetfulness in taking the OAT in the last month, with the most frequent being 1 or 2 doses (34%). 39% (n=19) of the patients reported having had at least one bleeding episode in the last month. All bleeding was mild and none was related to TAO. It should be noted that up to 31% (n=15) of patients reported having presented symptoms of stroke in the last month. However, after conducting a medical interview, it was found that they did not meet the criteria for stroke. 18% (9) of the patients reported having a scheduled intervention and requested an appointment to perform bridging therapy. In patients with VKAs (n=16), 94% (n=15) reported at least once being unaware of their TRT and, after performing an educational intervention, 75% (n=12) of patients reported having a TRT<65%. Those patients in whom TRT was confirmed<65% (9) were switched to DOACs. In patients with DOACs (n=33), in no case did the dose of OAT had to be adjusted. LOLA saved a total of 111h (10 hours per month) for the medical team in the follow-up of patients with AF and OAT. CONCLUSIONS The results of the study suggest that LOLATAO seems to be a tool to help in the management of chronic follow-up of patients with AF and OAT that reduces the burden of care with high rates of acceptance and satisfaction by patients. In addition, it allows the identification of relevant clinical situations that require medical interventions and highlights the lack of knowledge of patients of their pathology and the need to improve their education for greater empowerment. CLINICALTRIAL Not applicable
- Open Access
- 4 December 2023
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 7 (1) , e48987
Implementing Telemedicine in Clinical Practice in the First Digital Hematology Unit: Feasibility Study
Background: Currently, there are no telemedicine models that fully integrate all areas of hematology into daily practice. Objective: The objectives of this feasibility study were to assess the practicality of implementing telemedicine into our clinical practice in the first Digital Hematology Unit and propose an innovative integrative design for clinical practice. Methods: We designed the Digital Hematology Unit, which is a specific physical space dedicated to carrying out telemedicine and monitoring patients in a holistic way. Also, a satisfaction questionnaire was performed and health care indicators were measured. Results: In 2021, there were 1331 first visits and 7534 follow-up visits. Of the first visits, 12.2% (n=163) were face-to-face and 87.8% (n=1168) were telematic. For follow-up visits, 29.9% (n=2251) were face-to-face and 70.1% (n=5283) were telematic. The health care management indicators showed that we had a waiting time of less than 4 days and took less than 4 hours to answer interconsultations among specialists. Moreover, patients reported a high level of satisfaction with the services provided. Conclusions: Our Digital Hematology Unit, as a case of success, serves as an example of how innovative digital solutions can contribute to the quality of care and excellence in health care achieved through a digital transformation process led by hematologists.
- 4 December 2023
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 7 (1) , e48987
Open AccessImplementing Telemedicine in Clinical Practice in the First Digital Hematology Unit: Feasibility Study
Background: Currently, there are no telemedicine models that fully integrate all areas of hematology into daily practice. Objective: The objectives of this feasibility study were to assess the practicality of implementing telemedicine into our clinical practice in the first Digital Hematology Unit and propose an innovative integrative design for clinical practice. Methods: We designed the Digital Hematology Unit, which is a specific physical space dedicated to carrying out telemedicine and monitoring patients in a holistic way. Also, a satisfaction questionnaire was performed and health care indicators were measured. Results: In 2021, there were 1331 first visits and 7534 follow-up visits. Of the first visits, 12.2% (n=163) were face-to-face and 87.8% (n=1168) were telematic. For follow-up visits, 29.9% (n=2251) were face-to-face and 70.1% (n=5283) were telematic. The health care management indicators showed that we had a waiting time of less than 4 days and took less than 4 hours to answer interconsultations among specialists. Moreover, patients reported a high level of satisfaction with the services provided. Conclusions: Our Digital Hematology Unit, as a case of success, serves as an example of how innovative digital solutions can contribute to the quality of care and excellence in health care achieved through a digital transformation process led by hematologists.
- Open Access
- 14 May 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Implementing Telemedicine in Clinical Practice in the First Digital Hematology Unit: Feasibility Study (Preprint)
BACKGROUND Currently, there are no telemedicine models that fully integrate all areas of hematology into daily practice. OBJECTIVE The objectives of this feasibility study were to assess the practicality of implementing telemedicine into our clinical practice in the first Digital Hematology Unit and propose an innovative integrative design for clinical practice. METHODS We designed the Digital Hematology Unit, which is a specific physical space dedicated to carrying out telemedicine and monitoring patients in a holistic way. Also, a satisfaction questionnaire was performed and health care indicators were measured. RESULTS In 2021, there were 1331 first visits and 7534 follow-up visits. Of the first visits, 12.2% (n=163) were face-to-face and 87.8% (n=1168) were telematic. For follow-up visits, 29.9% (n=2251) were face-to-face and 70.1% (n=5283) were telematic. The health care management indicators showed that we had a waiting time of less than 4 days and took less than 4 hours to answer interconsultations among specialists. Moreover, patients reported a high level of satisfaction with the services provided. CONCLUSIONS Our Digital Hematology Unit, as a case of success, serves as an example of how innovative digital solutions can contribute to the quality of care and excellence in health care achieved through a digital transformation process led by hematologists.
- 14 May 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessImplementing Telemedicine in Clinical Practice in the First Digital Hematology Unit: Feasibility Study (Preprint)
BACKGROUND Currently, there are no telemedicine models that fully integrate all areas of hematology into daily practice. OBJECTIVE The objectives of this feasibility study were to assess the practicality of implementing telemedicine into our clinical practice in the first Digital Hematology Unit and propose an innovative integrative design for clinical practice. METHODS We designed the Digital Hematology Unit, which is a specific physical space dedicated to carrying out telemedicine and monitoring patients in a holistic way. Also, a satisfaction questionnaire was performed and health care indicators were measured. RESULTS In 2021, there were 1331 first visits and 7534 follow-up visits. Of the first visits, 12.2% (n=163) were face-to-face and 87.8% (n=1168) were telematic. For follow-up visits, 29.9% (n=2251) were face-to-face and 70.1% (n=5283) were telematic. The health care management indicators showed that we had a waiting time of less than 4 days and took less than 4 hours to answer interconsultations among specialists. Moreover, patients reported a high level of satisfaction with the services provided. CONCLUSIONS Our Digital Hematology Unit, as a case of success, serves as an example of how innovative digital solutions can contribute to the quality of care and excellence in health care achieved through a digital transformation process led by hematologists.